CrushSCI.com
Journal Selection & Manuscript Polishing Services
Transplantation and Cellular Therapy journal cover Medicine
Back to journal directory

Review Cycle Records

Transplantation and Cellular Therapy

Elsevier SCIE Non-OA
2026 Emerging Zone 22025 CAS Zone 32025 JCR Q1
76.7Average days
56Median days
14Fastest days
238Longest days
1,1372025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

71 days

Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis

AuthorsNeela Easton; Mia Andreoli; Herman van Besien; Caitlin Gribbin; Michelle Pasciolla; Anna Alperovich; Mateo Mejia Saldarriaga; Barbara Ma; Nora Chokr; Amer Assal; Joshua Fein; Sebastian Mayer; Alexandra Gomez Arteaga; Daniel Choi; Tsiporah Shore; Christopher S. Hackett; Juliet Barker; Samuel Yamshon

AffiliationsNewYork-Presbyterian/Weill Cornell, Hematology & Medical Oncology, New York, New York; NewYork-Presbyterian/Weill Cornell Medical Center, Medicine, New York, New York; Perlmutter Cancer Center, NYU Langone, New York, New York

Source PDF DOI Publisher page
55 days

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial

AuthorsMasahiro Onozawa; Shigeru Kusumoto; Yachiyo Kuwatsuka; Takayoshi Miyazono; Masatsugu Tanaka; Yuho Najima; Kohei Okada; Souichi Shiratori; Takayuki Sato; Junya Kanda; Yuichiro Inagaki; Tohru Murayama; Kaoru Hatano; Koichi Onodera; Masatoshi Sakurai; Shinya Endo; Takahiro Kumode; Hidehiro Itonaga; Yukiyoshi Moriuchi; Nobuhiro Kanemura; Tatsuya Imi; Taro Edahiro; Nobuaki Fukushima; Masahiro Oura; Shunsuke Yui; Mitsumasa Watanabe; Tomomi Toubai; Toshihiko Ando; Daisuke Nakamura; Masaharu Tamaki; Yasutaka Kakinoki; Takahiro Okada; Nobuaki Nakano; Takayoshi Tachibana; Hiroaki Shimizu; Shuichi Ota; Shinsuke Iida; Masaya Sugiyama; Yoshiko Atsuta; Takanori Teshima; Tomoharu Yoshizumi; Masashi Mizokami

AffiliationsDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan; Department of Hematology and Cell therapy, Aichi Cancer Center, Nagoya, Japan; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; Department of Hematology, Imamura General Hospital, Kagoshima, Japan; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan; Department of Hematology, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan; Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan; Department of Hematology, Hyogo Cancer Center, Akashi, Japan; Department of Medicine, Division of Hematology, Jichi Medical University, Shimotsuke, Japan; Department of Hematology, Tohoku University Hospital, Sendai, Japan; Department of Medicine, Division of Hematology, Keio University School of Medicine, Tokyo, Japan; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan; Hematology and Rheumatology, Kindai University, Osaka, Japan; Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan; Department of Hematology, Sasebo City General Hospital, Sasebo, Japan; Department of Hematology & Infectious Disease, Gifu University Hospital Gifu, Japan; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan; Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan; Department of Hematology, Nippon Medical School, Tokyo, Japan; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan; Department of Hematology and Cell Therapy, Yamagata University Hospital, Yamagata, Japan; Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University, Saga, Japan; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan; Department of Hematology, Shimane University Hospital, Izumo, Japan; Department of Viral Pathogenesis and Controls, National Institute of Global Health and Medicine, Japan Institute for Health Security, Kohnodai, Japan; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Genome Medical Sciences Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Konodai, Japan; Molecular and Cellular Glycoproteomics Research Group, Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan

Source PDF DOI Publisher page
50 days

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma

AuthorsLindsay Fogel; Patrick C. Roney; Jaeil Ahn; Joshua Zenreich; Adolfo Aleman; Kimberly Doucette; Palka Anand; Andrew Ip; Andre Goy; Tatyana Feldman; Lori Leslie; Andrew Pecora; Pooja Phull; Harsh Parmar; David Vesole; David S. Siegel; Noa Biran

AffiliationsHackensack Meridian School of Medicine, Nutley, New Jersey; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey

Source PDF DOI Publisher page
44 days

Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Prevalence

AuthorsMuhammad Kashif Amin; Nabeeha Noor; Muhammad Talha Maqsood; Hameer Ali; Hateem Ahmad; Huda Memon; Fatima Iqbal; Saniya Ishtiaq; Mahad Zamir; Momin Shaukat; Alma Habib; Moazzam Shahzad; Mehdi Hamadani; Joseph McGuirk; Muhammad Umair Mushtaq

AffiliationsDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas; The Mikael Rayaan Foundation Global Research Training Institute (MRF GRTI), Kansas City, Kansas; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas; Division of Hematology and Oncology, Moffitt Cancer Center, University of South Florida, Tampa, Florida; Medical College of Wisconsin, Milwaukee, Wisconsin

Source PDF DOI Publisher page
101 days

Cord Blood Transplantation versus Other Donor Sources in High-Risk Acute Myeloid Leukemia

AuthorsTatsuro Hirao; Hisashi Yamamoto; Mika Kuno; Otoya Watanabe; Kyosuke Yamaguchi; Kosei Kageyama; Daisuke Kaji; Yuki Taya; Aya Nishida; Shinsuke Takagi; Yuki Asano-Mori; Go Yamamoto; Atsushi Wake; Shuichi Taniguchi; Naoyuki Uchida

AffiliationsDepartment of Hematology, Toranomon Hospital, Tokyo, Japan; Centre for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan; Okinaka Memorial Institute for Medical Research, Tokyo, Japan; Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan; Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan; Centre for Cellular Therapy, Toranomon Hospital, Tokyo, Japan

Source PDF DOI Publisher page
48 days

Association of MRD Status With Survival Outcomes and Cytokine Release Syndrome in Outpatient Transplantation After Reduced-Intensity Conditioning for Acute Lymphoblastic Leukemia: Experience From a Low- and Middle-Income Country Reference Center

AuthorsJosé Carlos Jaime-Pérez; Alberto Villalón-López; Nereida Méndez-Ramírez; Rosario Salazar-Riojas; César Homero Gutiérrez-Aguirre; Olga Graciela Cantú-Rodríguez; David Gómez-Almaguer

AffiliationsHematology Department, Internal Medicine Division, Dr. José Eleuterio González University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Source PDF DOI Publisher page
89 days

Excellent Long-Term Survival and Immune Recovery With Reduced-Intensity Conditioning HCT in Inborn Errors of Immunity

AuthorsHannah Lust; Olatundun Williams; Jennifer Schneiderman; Reggie Duerst; David Jacobsohn; Angelo Rivera; Ramsay Fuleihan; William T. Tse; Morris Kletzel; Sonali Chaudhury

AffiliationsDivision of Hematology/Oncology/Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington, Seattle, Washington; Department of Pediatrics at George Washington University, Children’s National Hospital, Washington, District of Columbia; Mathews Center for Cellular Therapy, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Allergy & Immunology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky. Deceased.

Source PDF DOI Publisher page
14 days

Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks

AuthorsJoseph Farinella; Stephanie Farlow; Claudio Brunstein; Paolo F. Caimi

AffiliationsBone Marrow and Cellular Therapy Program, Cleveland Clinic Cancer Institute, Cleveland, Ohio; Case Comprehensive Cancer Center, Cleveland, Ohio

Source PDF DOI Publisher page
57 days

Donor Source Selection in Hematopoietic Cell Transplantation: Practices and Perceptions Across 50 United States Transplant Centers

AuthorsJaime M. Preussler; Jill Randall; Christa Meyer; Kim Wadsworth; Kelley Frederick; Traci Sutter; Paris McGhee; Ellen Denzen; Anna M. DeSalvo

AffiliationsCIBMTR® (Center for International Blood and Marrow Transplant Research) NMDP, Minneapolis, Minnesota; NMDP, Minneapolis, Minnesota

Source PDF DOI Publisher page
238 days

Increased Susceptibility to Long-Term Complications in Leukemia Survivors Who Received Hematopoietic Stem Cell Transplantation During Adolescence

AuthorsLéna Pessarossi; Marilyne Poirée; Jean-Hugues Dalle; Sandrine Visentin; Carine Domenech; Cécile Renard; Cécile Pochon; André Baruchel; Mony Fahd; Virginie Gandemer; Charlotte Jubert; Stéphane Ducassou; Catherine Paillard; Laura Olivier-Gougenheim; Alexandre Theron; Dominique Plantaz; Marie-Dominique Tabone; Guy Leverger; Justyna Kanold; Sandrine Thouvenin-Doulet; Zeinab Hamidou; Mohamed Boucekine; Julie Berbis; Pascal Auquier; Gérard Michel; Paul Saultier

AffiliationsDepartment of Pediatric Hematology, Immunology and Oncology, La Timone Children’s Hospital, Marseille, France; Pediatric Hematology and Oncology Department, University Hospital L’Archet, Nice, France; Hematology and Immunology Department, Robert Debré Hospital, GHU APHP Nord, Université de Paris, Paris, France; Department of Pediatric Hematology, Immunology and Oncology, Aix Marseille Univ, APHM, CERESS, La Timone Children’s Hospital, Marseille, France; Department of Pediatric Hematology and Oncology, IHOP, Hospices Civils de Lyon, Lyon 1 University, Lyon, France; Department of Pediatric Onco-Hematology, Hôpital d’Enfants de Brabois, Vandoeuvre Les Nancy, France; Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France; Department of Pediatric Hematology and Oncology, University Hospital of Bordeaux, Bordeaux, France; Department of Pediatric Hematology-oncology, University Hospital, Strasbourg, France; Department of Pediatric Hematology and Oncology, University Hospital of Toulouse, Toulouse, France; Department of Pediatric Hematology and Oncology, University Hospital, Montpellier, France; Department of Pediatric Hematology-Oncology, University Hospital of Grenoble, Grenoble, France; Department of Pediatric Hematology, Immunology and Oncology, Armand Trousseau Hospital, Sorbonne University, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; Department of Pediatric Hematology and Oncology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France; Department of Pediatric Hematology-Oncology, University Hospital St Etienne, St Etienne, France; Department of Public Health, Aix Marseille Univ, APHM, CERESS, Marseille, France; Department of Pediatric Hematology, Immunology and Oncology, Aix Marseille Univ, APHM, INSERM, INRAE, C2VN, La Timone Children’s Hospital, Marseille, France

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.